Copperhead Chemical Company, Inc. – FDA 483, Jun 18, 2026

An FDA inspection of Copperhead Chemical Company, Inc. in Tamaqua, PA, revealed significant deficiencies in manufacturing controls. Observations included inadequate cleaning validation for API drug substance equipment, insufficient out-of-specification investigation processes, and improper monitoring of warehouse storage temperatures. These issues indicate a lack of robust quality systems.